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Background: Over the last two decades, the proportion of people who inject drugs among newly reported HIV
cases in Italy has been continuously declining. This trend is reflected in the prevalence of HIV infection among
problem drug users followed in drug treatment services. We report nationwide trends in the prevalence of HIV and
HCV among tested clients in charge to drug addiction services from 2005 to 2011.
Methods: Data on the prevalence of HIV and HCV among drug users from public drug treatment services across
Italy were collected and analyzed for the period from 2005 to 2011. Prevalence of HIV and HCV were compared
between clients returning to treatment and those entering treatment for the first time, and by gender. Due to the
high percentage of missing data, the “inverse probability weight” method was used. Trends in testing uptake were
also analysed.
Results: A significant decrease of HIV and HCV prevalence is observed among all PDUs entering treatment (from
14.7% to 11.1% and from 61.6% to 50%, respectively, in 2005–2011). By contrast, among those entering the services
for the first time, after an initial decline the prevalence of HIV infection steadily increased in both sexes, from 2.2%
in 2009 to 5.3% in 2011. Self-reported injecting rates in this group decreased over time, and in 2011 the proportion
reporting drug injecting was lower among new clients than in people returning to services (14.5 vs. 34.4%). We also
observed a progressive and significant reduction in HIV and HCV testing in drug treatment services.
Conclusions: Changes in injection practice and type of drugs used, coupled with a concurrent reduction in HCV
prevalence, do not support drug injection as the main explanation for an increased HIV transmission in people
entering drug treatment services for the first time. While reductions in testing rates raise concerns over data quality,
the possibility of increased sexual transmission needs to be considered.
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In some European countries, particularly in East Europe,
HIV infection in people who inject drugs (PWID) is re-
emerging as a serious public health problem. Since 2001
and through 2011, data on newly diagnosed HIV infec-
tions and HIV prevalence suggested falling infection
rates in PWID in the European Union [1-3]. Also in Italy
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unless otherwise stated.with AIDS has been continuously decreasing, from
62.4% before 2001 to 17.6% in 2011/12 [4]. This may, at
least partly, follow from the increased availability of pre-
vention, treatment and harm-reduction measures, in-
cluding opiate substitution treatment and needle and
syringe programmes [3,5]. Other factors, such as the
decline in injecting drug use that has been reported in
some countries (e.g., United Kingdom, Norway), may
also have played an important role [6,7]. Recent data,
however, suggest that there is a continuing potential for
outbreaks of HIV infection among PWID in somel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[3,8-12].
Drug injecting has been associated with HIV transmis-
sion since the beginning of the epidemic in the early 80’
[13]; however the role of non-injection drug use in the
spread of HIV is still unclear [14-16]. Drug use by any
route (not just injection) can be associated with unsafe
sexual practices, potentially putting people at risk for ac-
quiring or transmitting HIV and other sexually transmit-
ted infections. In particular, stimulants, such as cocaine,
crack cocaine and methamphetamine, have been linked
to high-risk sexual behaviour [17-19]. Importantly, indi-
viduals who engage in high-risk sexual practices (e.g. sex
workers, men who have sex with men) may have a higher
prevalence of drug use than the general population so that
drug use may be associated with high HIV prevalence
even without being causally linked to high-risk sexual
behaviour [19-21].
In Italy, as in many other countries, HIV prevention
programmes for problem drug users (PDUs) have mainly
focused on HIV transmission through unsafe injecting
practices with less attention to sexual risk behaviours. It
has been noted that in many countries, including Italy,
Netherlands and USA, the prevalence of HIV infection
among non-injecting PDUs has increased (with a simul-
taneous decrease among PWID) and this increase has
been correlated with sexual transmission [22-25].
We analyze data obtained from the national network
of drug treatment centres in Italy to investigate the po-
tential role of HIV transmission through sexual contact
among non-injecting drug users and to identify HIV
trends in specific drug-using subgroups. Where available,
results of the HIV, HBV and HCV screening tests were
also analyzed.
Methods
There are 550 drug treatment services located through-
out Italy, offering free drug treatment, medical care and
psychological assistance on an outpatient basis. Attend-
ance is voluntary and, as defined by law, screening for
HIV, HBV and HCV should be offered to all new clients
entering the drug treatment services and to returning
clients. Data are continuously collected in each service
using standardised data forms, regarding: the number of
new clients and returning clients, gender, substance(s) of
abuse and, where available, results of the HIV, HBV and
HCV screening tests. Data are sent to the Ministry of
Health and to the Antidrug Policy Department in aggre-
gate format on an annual basis.
For the purpose of this study, we used aggregated data
on HIV, HCV and HBV prevalence among people regis-
tered in drug treatment services. Screening for HIV,
HBV and HCV is performed with enzyme-linked im-
munosorbent assays on venous blood specimens. In caseof HIV and/or HCV seropositivity, subjects are referred
to an Infectious diseases or Internal Medicine specialist.
Where available, results of HBV serology are interpreted
in order to detect subjects candidates to vaccination
(anti-HBs and anti-HBc negatives) and those with previ-
ous HBV vaccine or infection. Prevalence of HIV and
HCV were compared between clients returning to treat-
ment and those entering treatment for the first time,
and by gender. Trends in testing uptake were analyzed.
Data were analyzed from 2005 to 2011 using annual re-
ports from the Antidrug Policy Department. Utilization of
data collected in the study for scientific purposes was
approved by the Bioethics Committee of the Department
for antidrug policies.To compare proportions, we used the
chi-2 test for trend with double-side p-values. Due to the
high percentage of missing data on the raw prevalence of
HIV and HCV infection, and in order to reduce the im-
pact of the missing data on the final estimates, the “inverse
probability weight” method was used [26].Results
From 2005 to 2011 the Italian treatment monitoring sys-
tem documented between 162,005 and 174,156 clients
entering drug treatment services yearly (Table 1). Due to
inconsistencies in reporting serologic markers of HBV,
data on HBV infection are not reported. We observed a
progressive decrease in HIV and HCV screening cover-
age in drug addiction services, and these differences
were statistically significant (p < 0.0001 by χ2 for trend)
(Figure 1). The percentage of clients tested for HIV has
decreased from 40.6% in 2005 to 30.5% in 2011, and that
of clients tested for HCV from 46.5% in 2005 to 40.6%
in 2011 (Table 1, Figure 1). Of note, in 2011 only 21.9%
of female and 21.1% of male new clients were screened
for HIV, with 8.7% (86 women) and 5.5% (340 men) re-
spectively found to be HIV positive.By comparison, in
2005 35.5% of female and 32.4% of male new clients
were screened for HIV, with 3.7% of female and 3.3% of
male found positive. Due to the high percentage of miss-
ing data, the inverse probability weight method was used
to analyze data. Overall, prevalence of HIV infection in
patients registered in drug addiction services decreased
significantly, from 14.7% in 2005 to 11.1% in 2011. How-
ever, among those entering the services for the first time
(new clients), after an initial decline the prevalence of
HIV infection steadily increased in both sexes, from
2.2% in 2009 to 5.3% in 2011 (Table 1, Figure 2).
Data on HCV prevalence are shown in Figure 1 and
Table 1. HCV prevalence in patients attending drug
treatment services is high, but a steady and significant
decline has been observed during the last years both in
the overall population and in new clients. HCV infec-
tions decreased significantly from 61.6% to 50.0% in the
Table 1 Prevalence of HIV and HCV infection among clients registered in Drug addiction services in Italy
2005 2006 2007 2008 2009 2010 2011§
HIV prevalence:
Overall* (tested) 14.7 (65,848) 13.5 (67,300) 13.1 (68,032) 12.9 (64,021) 12.0 (60,057) 13.8 (58,408) 11.1 (45,663)
- new clients* (tested) 3.8 (11,562) 4.4 (11,520) 3.7 (12,165) 2.9 (11,214) 2.2 (9,821) 4.7 (9,860) 5.3 (7,154)
HCV prevalence:
Overall** (tested) 61.6 (75,354) 62.4 (78,212) 61.1 (80,366) 59.7 (74,631) 59.4 (71,777) 61.9 (74,374) 50.0 (56,227)
- new clients** (tested) 31.8 (11,739) 31.3 (11,371) 30.7 (12,475) 26.4 (11,718) 25.3 (10,591) 27.9 (10,190) 21.6 (8,462)
Sample size (No. subjects in drug
treatment services)
162,005 171,353 172,303 167,674 168,364 174,156 172,211
*p < 0.0001 by χ2 for trends, showing a decrease of prevalence of HIV infection in the overall population, and an increase of prevalence of HIV infection among
subjects entering Drug addiction services for the first time.
**p < 0.0001 by χ2 for trends, showing a decrease of prevalence of HCV infection in all categories of subjects.
§For the year 2011 data are incomplete, since some centres provided only anagraphic data; 172,211 clients entered drug treatment in 2011, but data on HIV and
HCV screening test were available from 138,475 subjects only. Due to the high percentage of missing data we used the “inverse probability weight” method.
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and from 31.8% to 21.6% in new clients (p <0.0001).
Among registered clients in 2011, 79.8% reported opi-
oids as the primary drug of abuse, followed by cocaine
in 12.6% and other substances (mostly cannabis) in 7.6%.
A different distribution was identified among new cli-
ents: 38.7% reported opioids as the primary drug, 30.8%
used cocaine, and 25.4% cannabis. Moreover, drug injec-
tion was reported by 14.5% of new clients (42.4% of those
reporting opioids as primary drug, and 3.9% of those
reporting cocaine) compared to 34.4% (58.1% of opioids
users, 7.3% of cocaine users) of overall clients. By com-
parison the 2005 data show a higher proportion of opioids
use (45.7%) and a lower cocaine use (26.5%) in new cli-
ents, and an overall higher proportion of injective use
(22.8% among new clients, and 67.3% among the overall
population).Figure 1 Temporal trends in HCV and HIV screening in Drug addiction ser
drug addiction services (p < 0.0001 by χ 2 for trends) was observed.Discussion
We report a marked increase in the prevalence of HIV
coupled with a decrease of HCV prevalence among
people entering drug treatment services for the first time
in Italy.
Changes in injection practice and type of drugs used,
coupled with a concurrent reduction in HCV prevalence,
do not support increases in drug injection risks as an ex-
planation for the increase in HIV transmission in this
group. A slightly higher HIV prevalence was observed
among women compared to men, possibly due to the
low number of women in the sample. However, the pro-
portion of HIV-positive women to HIV-positive men
(1:2.5) is similar to that reported in the surveillance sys-
tem for new HIV diagnoses (1:3) in 2011 [27]. Although
our monitoring system has national coverage and as
such provides key data on infectious diseases in PDU wevices in Italy. A significant decrease in HIV and HCV testing in clients of
Figure 2 HIV and HCV prevalence among new clients in Drug addiction services in Italy.
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to improve their relevance for public health.
Among injecting drug users, HIV is transmitted sexu-
ally and parenterally, but HCV is transmitted primarily
parenterally [28]. Recent evidence suggests that HIV
transmission in European countries (Greece, Romania)
reporting new outbreaks of HIV infection among inject-
ing drug users was preceded by increases in the preva-
lence of the HCV [2]. Rising HCV prevalence may act as
an early indicator of increases in injecting risks among
injecting drug user populations, possibly before HIV has
started to spread [28-30]. Given that the increase in HIV
prevalence among the new clients in our data is not as-
sociated with an increase in HCV prevalence, our data
thus seem not to support increases in injection risks as
an explanatory factor for the observed increase in HIV.
Data from the Italian National Institute of Health col-
lected in 2005 in a randomly selected sample of 1330 in-
dividuals with problematic drug use (defined according
to EMCDDA [31] as ‘injecting drug use or long-duration/
regular use of opioids, cocaine and/or amphetamines),
attending public drug treatment services, showed that the
prevalence of HIV was 14.4% among drug injectors and
1.6% among non-injectors; HCV prevalence was 83.2%
among injecting drug users and 22.0% among non-
injectors [22]. However, the percentage of individuals
tested for HIV in those centres has also decreased signifi-
cantly, from 40.6% in 2005 to 30.5% in 2011 (p < 0.0001 by
χ 2 for trends).
The progressive reduction of HIV and HCV testing is
also one of our main findings, based on a monitoring
system with nationwide coverage of drug addiction
population in charge to drug addiction services. Results
of a survey conducted in Italy in drug treatment services
underline the importance of facilitating access to testingand removing obstacles that can lead to the drug user's
refusal to undergo testing [32]. The failure to undergo
testing among injectors was associated with a shorter
history of drug use (<5 years) and with drug centres in
central or southern Italy; these associations were also
found among non-injectors, with the addition of low
level of education. Other reasons for this decline in testing
over time include a progressive reduction of resources for
public drug treatment services, and a decreased proportion
of drug users undergoing pharmacological-psychological
treatment (which involves a more complete monitoring
program) [33]. Moreover, main reasons for not undergoing
HIV testing were an individual’s refusal and lacking of a
blood drawing facility within the service. These results
underline the importance of facilitating access to testing, of
providing the drug dependency centres with the necessary
resources for taking blood samples at the centres them-
selves, of making access to testing uniform throughout the
country, and of removing obstacles that can lead to the
drug user's refusal to undergo testing.
In Italy, the government response to preventing infec-
tions among PDUs is mainly based on opioid substitu-
tion treatment (OST), detoxification and psychosocial
interventions, while needle and syringe programs (NSP)
are mainly implemented through NGOs in the setting of
outreach programmes with the training for PWIDs and
coverage is very low. Opioid agonist treatments are asso-
ciated with reductions in the frequency of opioid use,
fewer injections and injection-related risk behaviours
and lower rates of HIV/HCV prevalence and incidence
[34-36]. On the other hand, progressively less attention
has been given to periodic testing for HIV, HBV and
HCV [37].
The low percentage of PWID tested for HIV observed
in drug treatment services leads to a high proportion of
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presenters), correlated with a high probability of trans-
mitting HIV and worse clinical outcome [4,38,39]. In
Italy in 2012, PWID showed the highest proportion
(61.0%) of late presenters for HIV infection as compared
to heterosexuals or men who have sex with men [4].
This finding confirms that HIV testing is not routinely
performed on a year basis among PWID but rather at a
late stage when HIV-indicator diseases are diagnosed,
leading to a higher risk of death among PWID with
AIDS [40].
Likewise, screening for HCV in drug services remains
of utmost importance, since HCV prevalence among
injecting drug users remains high, and the availability of
improved HCV treatment is expected to reduce the dis-
ease burden. HIV/HCV co-infected drug users remain at
increased risk of dying from liver-related death in the
HAART era compared with HCV-mono-infected drug
users [41]. Moreover, recent reports show that among
Italian PWID liver disease is the most frequent non-
AIDS related cause of death [41].
Another point that deserves attention is the changing
epidemiology of problem drug use. In Europe, treatment
demand for stimulants (cocaine and amphetamine-type
stimulants) and cannabis have increased over time, in
parallel with a decline in treatment demands for opiates
[42]. Moreover, it has been suggested that the increasing
use of non-injecting drugs, such as recreational drugs,
may lead to an increased spread of infections through
sexual contact [23,36]. Such developments may partly
explain our findings for Italy.
Important limitations exist regarding the quality and
completeness of our data. First, the progressive reduc-
tion in HIV and HCV testing in drug treatment services
is of concern, as it can result in unpredictable biased
prevalence rates for viral infections, making prevalence
trends more difficult to interpret. Second, until present
only aggregate data on HIV prevalence are available,
which provide summary information but do not allow
more detailed epidemiological analysis, such as stratifying
seroprevalence rates by type of client, type of substance
used, or by route of drug administration.Conclusions
Changes in injection practice and type of drugs used,
coupled with a concurrent reduction in HCV prevalence,
do not support drug injection as the main explanation
for an increased HIV transmission in people entering
drug treatment services for the first time. While reduc-
tions in testing rates raise concerns over data quality,
the possibility of increased sexual transmission needs to
be considered. Evaluation of this hypothesis and planning
of possible effective interventions for reducing HIVtransmission via sexual behaviours among PDUs (irre-
spective of injective or non-injective use) is required.
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